Impact of quality control accepted inter-laboratory variations on calculated Fibrotest/Actitest scores for the non-invasive biochemical assessment of liver fibrosis

Clinica Chimica Acta

Volumn 409, Issue 1-2, 2009, Pages 90-95

  Gressner, Olav A ^a   Beer, Nina ^a   Jodlowski, Arkadius ^a   Gressner, Axel M ^a  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

Actitest; Fibrotest; Inter laboratory variations; Intra analytical variability; Liver biopsy; Reliability

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA 2 MACROGLOBULIN; APOLIPOPROTEIN A1; BILIRUBIN; GAMMA GLUTAMYLTRANSFERASE; HAPTOGLOBIN;

ACTITEST; ADULT; ARTICLE; BIOCHEMISTRY; CALCULATION; CASE REPORT; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; FIBROGENESIS; FIBROTEST; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER FIBROSIS; MALE; NON INVASIVE MEASUREMENT; PARAMETRIC TEST; PRIORITY JOURNAL; QUALITY CONTROL; SCORING SYSTEM; STAGING;

BLOOD CHEMICAL ANALYSIS; HUMANS; LABORATORIES; LIVER CIRRHOSIS; MALE; MIDDLE AGED; QUALITY CONTROL; REPRODUCIBILITY OF RESULTS;

EID: 70349810669     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2009.09.005     Document Type: Article

References (38)

1. Anderson R.N., and Smith B.L. Deaths: leading causes for 2001. Natl Vital Stat Rep 52 (2003) 1-85
2. Gressner O.A., Rizk M.S., Kovalenko E., Weiskirchen R., and Gressner A.M. Changing the pathogenetic roadmap of liver fibrosis? Where did it start - where will it go?. J Gastroenterol Hepatol 23 (2008) 1024-1035
3. Friedman S.L. Mechanisms of hepatic fibrogenesis. Gastroenterology 134 (2008) 1655-1669
4. Bedossa P., Dargere D., and Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 38 (2003) 1449-1457
5. Afdhal N.H., and Nunes D. Evaluation of liver fibrosis: a concise review. Am J Gastroenterol 99 (2004) 1160-1174
6. Gressner O.A., Weiskirchen R., and Gressner A.M. Biomarkers of liver fibrosis: clinical translation of molecular pathogenesis or based on liver-dependent malfunction tests. Clin Chim Acta 381 (2007) 107-113
7. Gressner O.A., Weiskirchen R., and Gressner A.M. Evolving concepts of liver fibrogenesis provide new diagnostic and therapeutic options. Comp Hepatol 6 (2007)
8. Bedossa P., and Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 24 (1996) 289-293
9. Imbert-Bismut F., Ratziu V., Pieroni L., Charlotte F., Benhamou Y., and Poynard T. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet 357 (2001) 1069-1075
10. Goodman Z.D. Grading and staging systems for inflammation and fibrosis in chronic liver diseases. J Hepatol 47 (2007) 598-607
11. The French METAVIR Cooperative Study Group. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology 20 (1994) 15-20
12. Bundesärztekammer. Richtlinie der Bundesärztekammer zur Qualitätssicherung quantitativer laboratoriumsmedizinischer Untersuchungen. Dtsch Ärztebl 98 (2001) A2747-A2759
13. Iredale J. Defining therapeutic targets for liver fibrosis: exploiting the biology of inflammation and repair. Pharmacol Res 58 (2008) 129-136
14. Zardi E.M., Dobrina A., Ambrosino G., Margiotta D., Polistina F., and Afeltra A. New therapeutic approaches to liver fibrosis: a practicable route?. Curr Med Chem 15 (2008) 1628-1644
15. Bravo A.A., Sheth S.G., and Chopra S. Liver biopsy. N Engl J Med 344 (2001) 495-500
16. Plebani M., and Burlina A. Biochemical markers of hepatic fibrosis. Clin Biochem 24 (1991) 219-239
17. Rockey D.C., and Bissell D.M. Noninvasive measures of liver fibrosis. Hepatology 43 (2006) S113-S120
18. Halfon P., Munteanu M., and Poynard T. FibroTest-ActiTest as a non-invasive marker of liver fibrosis. Gastroentérol Clin Bio 32 (2008) 22-39
19. Ngo Y., Benhamou Y., Thibault V., et al. An accurate definition of the status of inactive hepatitis B virus carrier by a combination of biomarkers (FibroTest-ActiTest) and viral load. PLoS ONE 3 (2008) e2573
20. Rosenthal-Allieri M.A., Tran A., Halfon P., et al. Optimal correlation between different instruments for Fibrotest-Actitest protein measurement in patients with chronic hepatitis C. Gastroentérol Clin Bio 31 (2007) 815-821
21. Morali G., Maor Y., Klar R., et al. Fibrotest-Actitest: the biochemical marker of liver fibrosis - the Israeli experience. Isr Med Assoc J 9 (2007) 588-591
22. Halfon P., Imbert-Bismut F., Messous D., et al. A prospective assessment of the inter-laboratory variability of biochemical markers of fibrosis (FibroTest) and activity (ActiTest) in patients with chronic liver disease. Comp Hepatol 1 (2002) 3
23. Imbert-Bismut F., Messous D., Thibaut V., et al. Intra-laboratory analytical variability of biochemical markers of fibrosis (Fibrotest) and activity (Actitest) and reference ranges in healthy blood donors. Clin Chem Lab Med 42 (2004) 323-333
24. Poynard T., Morra R., Halfon P., et al. Meta-analyses of FibroTest diagnostic value in chronic liver disease. BMC Gastroenterol 7 (2007)
25. Poynard T., McHutchison J., Manns M., Myers R.P., and Albrecht J. Biochemical surrogate markers of liver fibrosis and activity in a randomized trial of peginterferon alfa-2b and ribavirin. Hepatology 38 (2003) 481-492
26. Poynard T., Imbert-Bismut F., Munteanu M., et al. Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCV FibroSure) and necrosis (ActiTest) in patients with chronic hepatitis C. Comp Hepatol 3 (2004) 8
27. Rosenthal-Allieri M.A., Peritore M.L., Tran A., Halfon P., Benzaken S., and Bernard A. Analytical variability of the Fibrotest proteins. Clin Biochem 38 (2005) 473-478
28. Lisman T., van Leeuwen Y., Adelmeijer J., et al. Interlaboratory variability in assessment of the model of end-stage liver disease score. Liver Int 28 (2008) 1325-1327
29. Cholongitas E., Marelli L., Kerry A., et al. Different methods of creatinine measurement significantly affect MELD scores. Liver Transpl 13 (2007) 523-529
30. Ratziu V., Giral P., Munteanu M., et al. Screening for liver disease using non-invasive biomarkers (FibroTest, SteatoTest and NashTest) in patients with hyperlipidaemia. Aliment Pharmacol Ther 25 (2007) 207-218
31. Leroy V., Hilleret M.N., Sturm N., et al. Prospective comparison of six non-invasive scores for the diagnosis of liver fibrosis in chronic hepatitis C. J Hepatol 46 (2007) 775-782
32. Lackner C., Struber G., Liegl B., et al. Comparison and validation of simple noninvasive tests for prediction of fibrosis in chronic hepatitis C. Hepatology 41 (2005) 1376-1382
33. Leroy V., Halfon P., Bacq Y., et al. Diagnostic accuracy, reproducibility and robustness of fibrosis blood tests in chronic hepatitis C: a meta-analysis with individual data. Clin Biochem 41 (2008) 1368-1376
34. Rossi E., Adams L., Prins A., et al. Validation of the FibroTest biochemical markers score in assessing liver fibrosis in hepatitis C patients. Clin Chem 49 (2003) 450-454
35. Sebastiani G., Vario A., Guido M., et al. Stepwise combination algorithms of non-invasive markers to diagnose significant fibrosis in chronic hepatitis C. J Hepatol 44 (2006) 686-693
36. Burroughs A.K., and Cholongitas E. Non-invasive tests for liver fibrosis: encouraging or discouraging results?. J Hepatol 46 (2007) 751-755
37. Guha I.N. Back to the future with noninvasive biomarkers of liver fibrosis. Hepatology 49 (2009) 9-11
38. Fabris C., Smirne C., Toniutto P., et al. Usefulness of six non-proprietary indirect markers of liver fibrosis in patients with chronic hepatitis C. Clin Chem Lab Med 46 (2008) 253-259